Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for inflammatory and fibrotic diseases. The company operates within the biotechnology and life sciences industry, with a primary emphasis on immunology and fibrosis-related conditions that have significant unmet medical need. Chemomab’s activities are centered on research and development rather than commercial sales, and it does not currently generate product revenue.
The company’s core asset is CM-101, a humanized monoclonal antibody designed to inhibit the chemokine CCL24, which plays a role in inflammatory and fibrotic pathways. Chemomab’s strategic positioning is based on targeting a biologically validated pathway with potential applications across multiple diseases. The company was founded in Israel and advanced its development platform privately before becoming publicly listed on Nasdaq under the ticker CMMB following a merger with a special purpose acquisition company in 2021, which provided capital to advance its clinical programs.
Business Operations
Chemomab’s operations are primarily organized around a single operating segment focused on drug research and clinical development. The company’s activities include preclinical research, clinical trial execution, regulatory strategy, and intellectual property management related to CM-101 and related pipeline assets. As a clinical-stage company, Chemomab’s expenditures are largely allocated to research and development, clinical trials, and supporting scientific infrastructure.
Operationally, Chemomab relies on a combination of in-house scientific leadership and outsourced capabilities, including contract research organizations for clinical trials and manufacturing partners for biologics production. The company does not report commercial operations and has no approved products on the market. Any revenue generation to date has been limited to non-recurring items, such as collaboration-related income, where applicable, based on available public disclosures.
Strategic Position & Investments
Chemomab’s strategic direction centers on advancing CM-101 through mid- to late-stage clinical development, with an initial focus on primary sclerosing cholangitis (PSC), a rare chronic liver disease with limited treatment options. The company is also evaluating the potential of the same mechanism in additional inflammatory and fibrotic indications, leveraging a single-asset, multi-indication development strategy.
The company has not disclosed a broad portfolio of acquisitions or a diversified investment arm, and its capital allocation strategy has been primarily focused on internal development rather than external mergers or acquisitions. Chemomab’s investment activities are therefore concentrated on clinical trials, regulatory engagement, and expanding the potential therapeutic scope of its lead antibody through scientific validation in adjacent disease areas.
Geographic Footprint
Chemomab Therapeutics is headquartered in Israel, which serves as the center for its executive leadership and core research activities. The company maintains an international operational presence through clinical trial sites and external partners in North America and Europe, reflecting the global nature of clinical development for rare and chronic diseases.
While Chemomab does not operate manufacturing facilities of its own, its development programs have international reach due to multinational clinical trials and regulatory engagement in multiple jurisdictions. Its public listing on U.S. capital markets further anchors its presence in the United States, particularly with respect to investor relations and regulatory reporting.
Leadership & Governance
Chemomab is led by an executive team with experience in biotechnology, drug development, and corporate leadership within publicly listed life sciences companies. The leadership emphasizes a science-driven strategy focused on translational research and disciplined clinical execution aimed at addressing diseases with limited existing therapies.
Key executives include:
- Adi Mor – Chief Executive Officer
- Yaron Pereg – Chief Scientific Officer
Publicly available information confirms the company’s governance structure includes a board of directors with industry and scientific experience. Details regarding additional executive roles and changes in leadership beyond those listed above are data inconclusive based on available public sources.